Clinical Trial

SAVE-Care (Sodium Glucose Cotransporter-2 Inhibitors [SGLT2i] As Novel Gout Care) Trial

Study acronym: SAVE-Care
Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
SAVE-Care (Sodium Glucose Cotransporter-2 inhibitors \[SGLT2i\] As Novel Gout Care) Trial is a double-blind randomized placebo-controlled trial (RCT) designed to assess the effect of empagliflozin on serum urate \[SU\] levels of gout patients, as well as levels of highly-sensitivity C-reactive protein \[hsCRP\] and interleukin 6 \[IL-6\], and estimate gout flares over 3 months, in order to develop a full-scale RCT of clinical endpoints to directly inform gout care guidelines.
Protocol Amendment History 1 change
critical Recruitment opened 2026-06-05
Trial Details
NCT Number NCT06674109
Lead Sponsor Massachusetts General Hospital
Collaborators: National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Conditions Gout and Hyperuricemia
Enrollment 60 participants
Start Date 2026-07-01
Primary Completion 2028-02-01 (estimated)
Study Completion 2028-02-28 (estimated)
Updated on ClinicalTrials.gov 2026-08-05